

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM400889

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Agility Capital II, LLC		10/04/2016	Limited Liability Company: CALIFORNIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Emmaus Life Sciences, Inc.		
<b>Street Address:</b>	21250 Hawthorne, Suite 800		
<b>City:</b>	Torrance		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	90503		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	Emmaus Medical, Inc.		
<b>Street Address:</b>	21250 Hawthorne, Suite 800		
<b>City:</b>	Torrance		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	90503		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 10</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86963532	EMMAUS MEDICAL	
<b>Serial Number:</b>	86963456	EMMAUS	
<b>Registration Number:</b>	3514187	AMINOPURE	
<b>Serial Number:</b>	85582108	NOSIC	
<b>Serial Number:</b>	85582217	NOSIK	
<b>Serial Number:</b>	85582244	EMMAUS	
<b>Serial Number:</b>	85585574	EMMAUS MEDICAL	
<b>Registration Number:</b>	3544782	NUTRESTORE	
<b>Registration Number:</b>	3727236	NUTRESTORE	
<b>Serial Number:</b>	85912407	RIDSIC	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6506440520		

OP \$265.00 86963532

TRADEMARK

**Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.**

**Phone:** (650) 648-3802  
**Email:** patty@pattycheng.com  
**Correspondent Name:** Patty Cheng  
**Address Line 1:** 2625 MIDDLEFIELD ROAD, SUITE 215  
**Address Line 4:** PALO ALTO, CALIFORNIA 94306

<b>NAME OF SUBMITTER:</b>	Patty Cheng
<b>SIGNATURE:</b>	/s/ Patty Cheng
<b>DATE SIGNED:</b>	10/04/2016

**Total Attachments: 8**  
source=Emmaus - IP Release (Agility) - executed#page1.tif  
source=Emmaus - IP Release (Agility) - executed#page2.tif  
source=Emmaus - IP Release (Agility) - executed#page3.tif  
source=Emmaus - IP Release (Agility) - executed#page4.tif  
source=Emmaus - IP Release (Agility) - executed#page5.tif  
source=Emmaus - IP Release (Agility) - executed#page6.tif  
source=Emmaus - IP Release (Agility) - executed#page7.tif  
source=Emmaus - IP Release (Agility) - executed#page8.tif

RELEASE OF SECURITY INTEREST

This Release of Security Interest is made as of October 4, 2016, by Agility Capital II, LLC, a California limited liability company ("Lender"), in favor of Emmaus Life Sciences, Inc., a Delaware corporation ("Borrower") and Emmaus Medical, Inc. ("Guarantor"), with their principal place of business located at 21250 Hawthorne, Suite 800, Torrance, CA 90503. Each of Borrower and Guarantor are also referred to as a "Grantor".

Recitals

WHEREAS, each Grantor granted to Lender a security interest in certain intellectual property, including without limitation, the copyrights, patents and trademark items listed on Exhibits A, B and C attached hereto, respectively (collectively, the "Intellectual Property"), under an Intellectual Property Security Agreement dated as of April 18, 2016 (the "Security Agreement") which was recorded with the US Patent and Trademark Office as set forth on Exhibits B and C, respectively.

WHEREAS Borrower has no outstanding obligations to Lender under the terms of the Security Agreement, Lender agrees to release its security interest in the Intellectual Property.

Agreement

NOW THEREFORE, Lender agrees that it terminates and releases its security interest in the Intellectual Property and reconveys to each Grantor, without warranty or recourse, all interest of Lender in the Intellectual Property.

LENDER:

Agility Capital II, LLC

By: 

Name: DANIEL CORRY

Title: MANAGING MEMBER

**EXHIBIT A**

**Copyrights**

<b>Title</b>	<b>Registration Number</b>	<b>Registration</b>
None.		

## EXHIBIT B

### Patents

Lender's security interest was recorded at the US Patent and Trademark Office on April 21, 2016 at Reel Number 038337 and Frame Number 0082.

**Our Ref: None**

Country/Region: United States Patent No: 5,693,671  
Filed: May 1, 1996 Priority: None  
Title: L-Glutamine Therapy for Sickle Cell Diseases and Thalassemia  
Status: Issued December 2, 1997; in-licensed from the UC; all maintenance fees paid.

**Our Ref: EM-001.01**

Country/Region: United States  
Type: Provisional Patent Application Appl. No.: 61/629,633  
Filed: November 21, 2011 Priority: None  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Expired.

**Our Ref: EM-001.02**

Country/Region: United States  
Type: Non-provisional Patent Application Appl. No.: 13/694,301  
Filed: November 17, 2012 Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms  
Status: Pending; a Final Office Action rejecting all claims has been issued by the USPTO; a Request for Continued Examination will be filed allowing pursuit of modified claims.

**Our Ref: EM-001.20**

Country/Region: Patent Cooperation Treaty  
Type: PCT Application  
Appl. No.: PCT/US2012/000557  
Filed: November 17, 2012 Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Expired.

**Our Ref: EM-001.21**

Country/Region: Europe  
Type: Regional Phase Filing Appl. No.: 12850971.8  
Filed: May 21, 2014  
Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Pending.

**Our Ref: EM-001.28**

Country/Region: Brazil  
Type: National Phase Filing  
Appl. No.: BR 1 2014 011898 1  
Filed: May 16, 2014  
Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Pending.

**Our Ref: EM-001.29**

Country/Region: India

Type: National Phase Filing

Appl. No.: 1037/KOLNP/2014

Filed: May 15, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Pending.

**Our Ref: EM-001.39**

Country/Region: Philippines

Type: National Phase Filing Appl. No.: 1-2014-501052

Filed: May 9, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Pending.

**Our Ref: EM-001.40**

Country/Region: China

Type: National Phase Filing Appl. No.: 201280056399

Filed: May 20, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Pending.

**Our Ref: EM-001.41**

Country/Region: Indonesia

Type: National Phase Filing Appl. No.: P-00201402912

Filed: May 16, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms Status: Pending.

**Our Ref: EM-002.01**

Country/Region: United States

Type: Provisional Patent Application Appl. No.: 61/630,831

Filed: December 19, 2011 Priority: None

Title: Methods and Compositions for the Treatment of Diverticulosis Status: Expired.

**Our Ref: EM-002.02**

Country/Region: United States

Type: Non-provisional Patent Application Appl. No.: 13/694,592

Filed: December 19, 2011 Priority: US Appl. No. 61/630,831

Title: Methods and Compositions for the Treatment of Diverticulosis

Status: Pending; a Final Office Action rejecting all claims has been issued by the USPTO; a Request for Continued Examination will be filed allowing pursuit of modified claims.

**Our Ref: EM-002.20**

Country/Region: Patent Cooperation Treaty

Type: PCT Application

Appl. No.: PCT/US2012/000576

Filed: December 14, 2012 Priority: US Appl. No. 61/630,831

Title: Methods and Compositions for the Treatment of Diverticulosis Status: Expired.

**Our Ref: EM-002.21**

Country/Region: Europe  
Type: Regional Phase Filing Appl. No.: 12860587.0  
Filed: June 25, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.24**

Country/Region: Australia  
Type: National Phase Filing Appl. No.: 2012355956  
Filed: June 9, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.26**

Country/Region: Mexico  
Type: National Phase Filing Appl. No.: MX/a/2014/007382  
Filed: June 18, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.28**

Country/Region: Brazil  
Type: National Phase Filing  
Appl. No.: BR 11 2014 014765 5  
Filed: June 16, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.29**

Country/Region: India  
Type: National Phase Filing  
Appl. No.: 1255/KOLNP/2014  
Filed: June 10, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.38**

Country/Region: Korea  
Type: National Phase Filing Appl. No.: 10-2014-7016785  
Filed: June 19, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.40**

Country/Region: China  
Type: National Phase Filing Appl. No.: To Be determined Filed: June 18, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.41**

Country/Region: Indonesia

Type: National Phase Filing Appl. No.: P-00201403584

Filed: June 18, 2014

Priority: US Appl. No. 61/630,831

Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-002.43**

Country/Region: Russia

Type: National Phase Filing Appl. No.: 2014123433

Filed: June 9, 2014

Priority: US Appl. No. 61/630,831

Title: Methods and Compositions for the Treatment of Diverticulosis Status: Pending.

**Our Ref: EM-003.01**

Country/Region: United States

Type: Invention Disclosure Appl. No.: To Be determined Filed: To Be Determined Priority: None

Title: To Be Determined

Status: Invention disclosure directed to combination therapy involving glutamine and alkali therapy (*e.g.*, sodium bicarbonate). Application in process.

**Our Ref: EM-004.01**

Country/Region: United States

Type: Invention Disclosure

Appl. No.: To Be Determined Filed: To Be Determined Priority: None

Title: To Be Determined

Status: Invention disclosure directed to combination therapy involving glutamine and hydroxyurea. Application in process.

**Our Ref: EM-005.01**

Country/Region: United States

Type: Invention Disclosure

Appl. No.: To Be Determined Filed: To Be Determined Priority: None

Title: To Be Determined

Status: Invention disclosure directed to combination therapy involving glutamine and various agents, including statins, nitric oxide and nitric oxide stimulating/releasing compounds, and agents that boost production of fetal hemoglobin. Application in process.

**Our Ref: EM-006.01**

Country/Region: United States

Type: Invention Disclosure

Appl. No.: To Be Determined Filed: To Be Determined Priority: None

Title: To Be Determined

Status: Invention disclosure directed to reduction of side effects in children based on a dosing regimen of glutamine. Application in process.



## EXHIBIT C

### Trademarks

Lender's security interest was recorded at the US Patent and Trademark Office on April 21, 2016 at Reel Number 5775 and Frame Number 0004.

Country/Region: United States  
Type: Trademark for EMMAUS MEDICAL  
Application No.: 86963532  
Filing Date: April 4, 2016

Country/Region: United States  
Type: Trademark for EMMAUS  
Application No.: 86963456  
Filing Date: April 4, 2016

**Our Ref: EM-501.00**

Country/Region: United States  
Type: Trademark for AMINOPURE Registration No.: 3,514,187  
Reg. Date: October 7, 2008  
Status: Registered; Declaration of Use due, without extension, October 7, 2014.

**Our Ref: EM-501.25**

Country/Region: Taiwan  
Type: Trademark for AMINOPURE Registration No.: 01546380  
Reg. Date: November 1, 2012  
Status: Registered; Extension due October 31, 2022.

**Our Ref: EM-501.36**

Country/Region: Ghana  
Type: Trademark for AMINOPURE Application No.: 000128/2012  
Status: Allowed, awaiting certificate of registration.

**Our Ref: EM-501.37**

Country/Region: Kenya  
Type: Trademark for AMINOPURE Application No.: 77713  
Status: Published for opposition.

**Our Ref: EM-501.38**

Country/Region: Korea  
Type: Trademark for AMINOPURE Registration No.: 45-0042982  
Reg. Date: January 3, 2013  
Status: Registered; Extension due January 4, 2022.

**Our Ref: EM-501.39**

Country/Region: Philippines  
Type: Trademark for AMINOPURE Registration No.: 4-2012-000514  
Reg. Date: April 26, 2012  
Status: Registered; Declaration of Use due January 13, 2015. Our Ref: EM-501.40

**Our Ref: EM-501.40**

Country/Region: China

Type: Trademark for AMINOPURE Application No.: To Be Determined Status: Filed; pending.

**Our Ref: EM-501.41**

Country/Region: Indonesia

Type: Trademark for AMINOPURE Application No.: To Be Determined Status: Filed; pending.

**Our Ref: EM-501.42**

Country/Region: Malaysia

Type: Trademark for AMINOPURE Application No.: To Be Determined Status: Filed; pending.

**Our Ref: EM-502.00**

Country/Region: United States

Type: Trademark for NOSIC Application No.: 85-582,108

Status: Allowed; Statement of Use or extension due August 4, 2014. This case was the subject of an opposition proceeding, Opposition 91211282, which was terminated on December 21, 2013.

**Our Ref: EM-503.00**

Country/Region: United States

Type: Trademark for NOSIK Application No.: 85-582,217

Status: Allowed; Statement of Use or extension due September 11, 2014. This case was the subject of an opposition proceeding, Opposition 91211284, which was terminated on January 24, 2014.

**Our Ref: EM-504.00**

Country/Region: United States

Type: Trademark for EMMAUS Application No.: 85-582,244

Status: Allowed; Statement of Use or extension due October 8, 2014.

**Our Ref: EM-504.00**

Country/Region: United States

Type: Trademark for EMMAUS MEDICAL Application No.: 85-585,574

Status: Allowed; Statement of Use or extension due October 8, 2014.

**Our Ref: EM-506.00**

Country/Region: United States

Type: Trademark for NUTRESTORE Registration No.: 3,544,782

Reg. Date: December 9, 2008

Status: Registered; Declaration of Use due, without extension, December 9, 2014.

**Our Ref: EM-507.00**

Country/Region: United States

Type: Trademark for NUTRESTORE (stylized) Registration No.: 3,727,236

Reg. Date: October 6, 2009

Status: Registered; Declaration of Use due, without extension, October 6, 2015.

**Our Ref: EM-508.00**

Country/Region: United States

Type: Trademark for RIDSIC Application No.: 85-912,407

Status: Allowed; Statement of Use or extension due December 3, 2014.